Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Virginia Pomar Solchaga

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Medicina Clinica|April 17, 2009
[Soft tissue infections]Mónica Ibáñez Barceló, Virginia Pomar Solchaga, Santos Castañeda
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|January 12, 2026
[Risk factors associated with inadequacy of empirical treatment in patients with sepsis and bacteremia attended in an emergency department]Meritxell Motos-Bescós, Jesús Ruiz-Ramos, Ivan Agra-Montava, et al.
BMJ Open Respiratory Research|December 8, 2025
Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protocolLaura Diab Casares, Juan Espinosa Pereiro, María Teresa Tórtola Fernández, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Medicina Clinica|April 17, 2009
[Soft tissue infections]Mónica Ibáñez Barceló, Virginia Pomar Solchaga, Santos Castañeda
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|January 12, 2026
[Risk factors associated with inadequacy of empirical treatment in patients with sepsis and bacteremia attended in an emergency department]Meritxell Motos-Bescós, Jesús Ruiz-Ramos, Ivan Agra-Montava, et al.
BMJ Open Respiratory Research|December 8, 2025
Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protocolLaura Diab Casares, Juan Espinosa Pereiro, María Teresa Tórtola Fernández, et al.
Pageof 1